New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
06:43 EDTHZNPHorizon Pharma downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Horizon Pharma to Neutral citing uncertainty following decisions by CVS Caremark and Express Scripts to exclude Duexis and Vimovo from their formularies effective 1/1/15. Piper lowered its price target for shares to $9 from $22.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:42 EDTHZNPPOZEN receives three patents from USPTO
POZEN (POZN) announced that it has received three patents from the United States Patent and Trademark Office, entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO. All three patents are expected to expire in 2022. Horizon Pharma (HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use